Evidence map›Paper›PMID 41819607›Full record

ArticleContact dermatitis2026

Patch Test Results With the European Baseline Series, 2021/2022-Joint European Results of the ESSCA

Wolfgang Uter, S Mark Wilkinson, Olivier Aerts, Andrea Bauer, Leopoldo Borrego, Richard Brans, Timo Buhl, Heinrich Dickel, Aleksandra Dugonik, Francesca Larese Filon and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Contact dermatitis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Wolfgang UterDepartment of Medical Informatics, Biometry and Epidemiology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.ORCID https://orcid.org/0000-0002-4498-3710
S Mark WilkinsonDermatology Department, Leeds Teaching Hospitals NHS Trust, Leeds, UK.ORCID https://orcid.org/0000-0001-7253-3461
Olivier AertsDepartment of Dermatology, University Hospital Antwerp (UZA) and Research Group Immunology, Infla-Med Centre of Excellence, University of Antwerp, Antwerp, Belgium.ORCID https://orcid.org/0000-0002-0076-2887
Andrea BauerDepartment of Dermatology, University Hospital Carl Gustav Carus, Technical University, Dresden, Germany.ORCID https://orcid.org/0000-0002-4411-3088
Leopoldo BorregoComplejo Hospitalario Universitario Insular Materno Infantil, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.ORCID https://orcid.org/0000-0002-0199-2756
Richard BransInstitute for Interdisciplinary Dermatologic Prevention and Rehabilitation (iDerm) at the Osnabrück University, Osnabrück, Germany.ORCID https://orcid.org/0000-0002-1245-024X
Timo BuhlDepartment of Dermatology, Venereology and Allergology, University Medical Center Göttingen, Göttingen, Germany.ORCID https://orcid.org/0000-0002-3139-129X
Heinrich DickelDepartment of Dermatology, Venereology and Allergology, St. Josef Hospital, University Medical Center, Ruhr University Bochum, Bochum, Germany.ORCID https://orcid.org/0000-0001-6837-4402
Aleksandra DugonikDepartment of Dermatology, University Medical Centre Maribor, Maribor, Slovenia.ORCID https://orcid.org/0000-0001-9454-7207
Francesca Larese FilonDepartment of Medical, Surgical and Health Sciences, Occupational Medicine, University of Trieste, Trieste, Italy.ORCID https://orcid.org/0000-0002-7717-0417
Ana Giménez ArnauDepartment of Dermatology, Hospital del Mar, Research Institute, Universitat Pompeu Fabra de Barcelona, Barcelona, Spain.ORCID https://orcid.org/0000-0001-5434-7753
Cataldo PatrunoDepartment of Medicine and Health Sciences "Vincenzo Tiberio", University of Molise, Campobasso, Italy.ORCID https://orcid.org/0000-0001-8661-2822
Györgyi PónyaiDepartment of Dermatology, Venerology and Dermato-Oncology, Semmelweis University, Budapest, Hungary.ORCID https://orcid.org/0000-0002-1695-6133
Stamatis GregoriouDepartment of Dermatology, Faculty of Medicine, National and Kapodistrian University of Athens, Athens, Greece.ORCID https://orcid.org/0000-0002-7585-1032
Steffen SchubertInformation Network of Departments of Dermatology (IVDK), Institute at the Georg-August University Göttingen, University Medical Centre Göttingen, Göttingen, Germany.ORCID https://orcid.org/0000-0002-2359-2518
Dagmar SimonDepartment of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.ORCID https://orcid.org/0000-0001-8965-9407
Luca StingeniDermatology Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.ORCID https://orcid.org/0000-0001-7919-8141
Skaidra ValiukevičienėDepartment of Skin and Venereal Diseases, The Hospital of Lithuanian University of Health Sciences Kauno Klinikos, Kaunas, Lithuania.ORCID https://orcid.org/0000-0003-1219-5928
Elke WeisshaarOccupational Dermatology, Department of Dermatology, University Hospital Heidelberg, Heidelberg, Germany.ORCID https://orcid.org/0000-0002-7016-0224
Thomas WerfelDepartment of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.ORCID https://orcid.org/0000-0001-6830-7672
Margarida GonçaloDepartment of Dermatology, University Hospital and Faculty of Medicine, University of Coimbra, Coimbra, Portugal.ORCID https://orcid.org/0000-0001-6842-1360
Marie-L A SchuttelaarDepartment of Dermatology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.ORCID https://orcid.org/0000-0002-0766-4382
ESSCAA and EBSB ESCD Working Groups, and the GEIDACC

Funding

Agencia Española de Medicamentos y Productos SanitariosFundación Piel SanaLEO PharmaSanofi España
6 · The paper itself

Abstract

backgroundPatch test results obtained with the European Baseline Series (EBS) in its current version serve both contact allergy surveillance and (re-)assessing the diagnostic value of EBS allergens.

objectivesTo present results of current EBS patch testing, obtained in 59 departments in 14 European countries during 2021 and 2022.

methodsAnonymised or pseudonymised individual data, and partly aggregated results, on demographic/clinical characteristics and patch test results with the EBS were prospectively collected, centrally pooled, and retrospectively analysed.

resultsIn 2021 and 2022, 18 832 patients were patch tested with the EBS. Sensitization to nickel remained most common (18.85 (18.29-19.43)% positivity (95% confidence interval)). Fragrance mix I and Myroxylon pereirae resin yielded very similar results with 6.39 (6.04-6.76)% and 6.5 (6.15-6.87)% positivity, respectively. Concerning preservatives, methylchloroisothiazolinone/methylisothiazolinone (MCI/MI) 0.02% aq. yielded 5.52 (5.11-5.96)% and MI 0.2% aq. yielded 5.28 (4.94-5.64)% positives. Testing formaldehyde 2% aq. identified almost one percentage point more positive reactions than 1% aq. (2.05 (1.81-2.32)% vs. 1.22 (0.99-1.48)). Positive reactions to the recently added allergens were most frequently seen to propolis (5.47 (5.12-5.84)%) and 2-hydroxyethyl methacrylate (3.63 (3.32-3.96)%).

conclusionsCompared to the previous reporting period, surveillance results with the EBS were mostly stable. The results regarding Quaternium 15 (0.4 (0.29-0.53)% positives) justified its exclusion from the 2023 EBS version.

Indexed as

AllergensDermatitis, Allergic ContactPatch TestsEuropeFemaleHumansPerfumeRetrospective StudiesThiazolesAllergensPerfumeThiazolesbaseline seriesclinical epidemiologycontact allergypatch testingRRID:SCR_001905surveillance

Identifiers

PMID41819607
PMCPMC13238334

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.